Alzheimer's disease in Down syndrome :: An overlooked population for prevention trials

André Strydom; Antonia Coppus; Rafael Blesa; Adrian Danek; Juan Fortea; John Hardy; Johannes Levin; Georg Nuebling; Anne-Sophie Rebillat; Craig Ritchie; Cornelia van Duijn; Shahid Zaman; Henrik Zetterberg

doi:10.1016/j.trci.2018.10.006

Alzheimer's disease in Down syndrome : An overlooked population for prevention trials

André Strydom, Antonia Coppus, Rafael Blesa, Adrian Danek, Juan Fortea, John Hardy, Johannes Levin, Georg Nuebling, Anne-Sophie Rebillat, Craig Ritchie, Cornelia van Duijn, Shahid Zaman, Henrik Zetterberg

Departament de Medicina

National Institute for Health and Care Research (NIHR) Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London
Universitat de Barcelona-Fundació Catalana Síndrome de Down

Producció científica: Contribució a revista › Article › Recerca › Avaluat per experts

91 Cites (Scopus)

Resum

The discovery that adults with Down syndrome (DS) have neuropathological features identical to individuals with sporadic Alzheimer's disease (AD) played a key role in the identification of the amyloid precursor protein gene on chromosome 21 and resulted in the amyloid cascade hypothesis. Individuals with DS have a lifetime risk for dementia in excess of 90%, and DS is now acknowledged to be a genetic form of AD similar to rare autosomal-dominant causes. Just as DS put the spotlight on amyloid precursor protein mutations, it is also likely to inform us of the impact of manipulating the amyloid pathway on treatment outcomes in AD. Ironically, however, individuals with DS are usually excluded from AD trials. This review will discuss primary and secondary prevention trials for AD in DS and the potential barriers and solutions to such trials and describe the Europe-wide Horizon21 Consortium to establish a DS-AD prevention clinical trials network.

Idioma original	Anglès
Pàgines (de-a)	0703-713
Nombre de pàgines	11
Revista	Alzheimer's and Dementia: Translational Research and Clinical Interventions
Volum	4
DOIs	https://doi.org/10.1016/j.trci.2018.10.006
Estat de la publicació	Publicada - 2018

Accés al document

10.1016/j.trci.2018.10.006

https://ddd.uab.cat/record/204202

Altres arxius i enllaços

https://www.scopus.com/pages/publications/85058170814

Com citar-ho

Strydom, A., Coppus, A., Blesa, R., Danek, A., Fortea, J., Hardy, J., Levin, J., Nuebling, G., Rebillat, A.-S., Ritchie, C., van Duijn, C., Zaman, S., & Zetterberg, H. (2018). Alzheimer's disease in Down syndrome : An overlooked population for prevention trials. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 4, 0703-713. https://doi.org/10.1016/j.trci.2018.10.006

@article{5400b940cee34770bddb9d001e658ecf,

title = "Alzheimer's disease in Down syndrome :: An overlooked population for prevention trials",

abstract = "The discovery that adults with Down syndrome (DS) have neuropathological features identical to individuals with sporadic Alzheimer's disease (AD) played a key role in the identification of the amyloid precursor protein gene on chromosome 21 and resulted in the amyloid cascade hypothesis. Individuals with DS have a lifetime risk for dementia in excess of 90\%, and DS is now acknowledged to be a genetic form of AD similar to rare autosomal-dominant causes. Just as DS put the spotlight on amyloid precursor protein mutations, it is also likely to inform us of the impact of manipulating the amyloid pathway on treatment outcomes in AD. Ironically, however, individuals with DS are usually excluded from AD trials. This review will discuss primary and secondary prevention trials for AD in DS and the potential barriers and solutions to such trials and describe the Europe-wide Horizon21 Consortium to establish a DS-AD prevention clinical trials network.",

keywords = "Alzheimer's disease, Down syndrome, Trisomy 21, Randomized controlled trials, Prevention, Dementia, APP, Amyloid, Biomarkers",

author = "Andr{\'e} Strydom and Antonia Coppus and Rafael Blesa and Adrian Danek and Juan Fortea and John Hardy and Johannes Levin and Georg Nuebling and Anne-Sophie Rebillat and Craig Ritchie and \{van Duijn\}, Cornelia and Shahid Zaman and Henrik Zetterberg",

year = "2018",

doi = "10.1016/j.trci.2018.10.006",

language = "English",

volume = "4",

pages = "0703--713",

journal = "Alzheimer's and Dementia: Translational Research and Clinical Interventions",

issn = "2352-8737",

publisher = "Elsevier Inc.",

}

Strydom, A, Coppus, A, Blesa, R, Danek, A, Fortea, J, Hardy, J, Levin, J, Nuebling, G, Rebillat, A-S, Ritchie, C, van Duijn, C, Zaman, S & Zetterberg, H 2018, 'Alzheimer's disease in Down syndrome : An overlooked population for prevention trials', Alzheimer's and Dementia: Translational Research and Clinical Interventions, vol. 4, pàg. 0703-713. https://doi.org/10.1016/j.trci.2018.10.006

TY - JOUR

T1 - Alzheimer's disease in Down syndrome :

T2 - An overlooked population for prevention trials

AU - Strydom, André

AU - Coppus, Antonia

AU - Blesa, Rafael

AU - Danek, Adrian

AU - Fortea, Juan

AU - Hardy, John

AU - Levin, Johannes

AU - Nuebling, Georg

AU - Rebillat, Anne-Sophie

AU - Ritchie, Craig

AU - van Duijn, Cornelia

AU - Zaman, Shahid

AU - Zetterberg, Henrik

PY - 2018

Y1 - 2018

N2 - The discovery that adults with Down syndrome (DS) have neuropathological features identical to individuals with sporadic Alzheimer's disease (AD) played a key role in the identification of the amyloid precursor protein gene on chromosome 21 and resulted in the amyloid cascade hypothesis. Individuals with DS have a lifetime risk for dementia in excess of 90%, and DS is now acknowledged to be a genetic form of AD similar to rare autosomal-dominant causes. Just as DS put the spotlight on amyloid precursor protein mutations, it is also likely to inform us of the impact of manipulating the amyloid pathway on treatment outcomes in AD. Ironically, however, individuals with DS are usually excluded from AD trials. This review will discuss primary and secondary prevention trials for AD in DS and the potential barriers and solutions to such trials and describe the Europe-wide Horizon21 Consortium to establish a DS-AD prevention clinical trials network.

AB - The discovery that adults with Down syndrome (DS) have neuropathological features identical to individuals with sporadic Alzheimer's disease (AD) played a key role in the identification of the amyloid precursor protein gene on chromosome 21 and resulted in the amyloid cascade hypothesis. Individuals with DS have a lifetime risk for dementia in excess of 90%, and DS is now acknowledged to be a genetic form of AD similar to rare autosomal-dominant causes. Just as DS put the spotlight on amyloid precursor protein mutations, it is also likely to inform us of the impact of manipulating the amyloid pathway on treatment outcomes in AD. Ironically, however, individuals with DS are usually excluded from AD trials. This review will discuss primary and secondary prevention trials for AD in DS and the potential barriers and solutions to such trials and describe the Europe-wide Horizon21 Consortium to establish a DS-AD prevention clinical trials network.

KW - Alzheimer's disease

KW - Down syndrome

KW - Trisomy 21

KW - Randomized controlled trials

KW - Prevention

KW - Dementia

KW - APP

KW - Amyloid

KW - Biomarkers

UR - https://www.scopus.com/pages/publications/85058170814

U2 - 10.1016/j.trci.2018.10.006

DO - 10.1016/j.trci.2018.10.006

M3 - Article

C2 - 30581976

SN - 2352-8737

VL - 4

SP - 703

EP - 713

JO - Alzheimer's and Dementia: Translational Research and Clinical Interventions

JF - Alzheimer's and Dementia: Translational Research and Clinical Interventions

ER -

Alzheimer's disease in Down syndrome : An overlooked population for prevention trials

Resum

Accés al document

Altres arxius i enllaços

Fingerprint

Com citar-ho